Combination therapy with a short-acting erythropoiesis-stimulating agent and epoetin beta pegol eliminated the need for blood transfusions in a hemodialysis patient with myelodysplastic syndrome | Zendy

AI Assistant Blog Pricing

Combination therapy with a short-acting erythropoiesis-stimulating agent and epoetin beta pegol eliminated the need for blood transfusions in a hemodialysis patient with myelodysplastic syndrome

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.